Investment caseThe HBM/DRAM mainline — direct beneficiary of capacity booked out to 2027-28.
Size / market capFY26Q3 revenue $41.5B in a single quarter (16% ahead of consensus), net income $28.2B (+12x).
Scarcity / moatThe only US-domiciled DRAM/HBM major — geopolitical scarcity.
CompetitionSKHY (~60% HBM share, now trading alongside) and Samsung.
RiskAn 84.9% gross margin is itself a cycle-top characteristic, not a strength.
Research framework, not investment advice. Specific levels, stops and sizing are Pro content.